CRISPR

CRISPR2-dre-mir-24-4

ID
ZDB-CRISPR-170626-6
Name
CRISPR2-dre-mir-24-4
Previous Names
  • CRISPR2-mir24-4
Target
Sequence
5' - TCAGTATGTTGATTTAGTGC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
ya327 dre-mir-24-4
Expression
Gene expression in Wild Types + CRISPR2-dre-mir-24-4
No data available
Phenotype
Phenotype resulting from CRISPR2-dre-mir-24-4
No data available
Phenotype of all Fish created by or utilizing CRISPR2-dre-mir-24-4
Phenotype Fish Conditions Figures
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-1ya324/ya324; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-1ya324/ya324; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-2ya325/ya325; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-2ya325/ya325; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg chemical treatment by environment: 6-bromoindirubin-3'-oxime Fig. 6 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg chemical treatment by environment: EC 3.4.23.46 (memapsin 2) inhibitor Fig. 6 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg hypoxia Fig. 6 with image from Kasper et al., 2017
hypobranchial artery increased variability of size, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg chemical treatment by environment: semaxanib Fig. 6 with image from Kasper et al., 2017
hypobranchial artery decreased length, abnormal dre-mir-24-4ya327/ya327; mir24-3ya326/ya326; mir24-1ya324/ya324; mir24-2ya325/ya325; la116Tg control Fig. 4 with image from Kasper et al., 2017
Citations